Welcome to our dedicated page for Harmony Biosciences Holdings news (Ticker: HRMY), a resource for investors and traders seeking the latest updates and insights on Harmony Biosciences Holdings stock.
Harmony Biosciences Holdings, Inc. develops and commercializes therapies for rare neurological diseases, with WAKIX® (pitolisant) as its commercial product for adult narcolepsy-associated cataplexy. News about HRMY centers on WAKIX revenue trends, market access and payer dynamics, intellectual-property protection, and product guidance.
Company updates also cover clinical and regulatory progress across its CNS pipeline, including pitolisant lifecycle programs and candidates such as EPX-100 for Dravet syndrome and Lennox-Gastaut syndrome. Recurring announcements include quarterly results, investor-conference presentations, executive and board changes, and pipeline data presentations at medical meetings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 24, 2023, Harmony Biosciences (Nasdaq: HRMY) appointed Jeffrey M. Dayno, M.D., as President and Chief Executive Officer. Dr. Dayno, who has been with the company since its inception in 2017 and has served as Interim CEO since January 2023, aims to enhance the WAKIX franchise, targeting both narcolepsy and potential new indications. The Board supports his vision for growth, anticipating a $1 billion market opportunity for WAKIX. Harmony focuses on developing therapies for rare neurological diseases and has been successful in obtaining FDA approval for WAKIX, which has been available in the U.S. since Q4 2019. The company emphasizes its commitment to innovative treatments for patients, as highlighted by Dr. Dayno's extensive experience in the field.
Harmony Biosciences Holdings (NASDAQ: HRMY) announced that it will release its first quarter 2023 financial results on May 2, 2023, before the U.S. financial markets open. A conference call will be held on the same day at 8:30 a.m. ET to discuss the results. Investors can participate by dialing (800) 343-4136 for domestic calls or +1 (203) 518-9843 for international calls, referencing passcode HRMYQ123. The live and replayed webcast will be accessible on the company’s investor page.
Harmony Biosciences focuses on developing therapies for rare neurological diseases, emphasizing innovation and empathy. Established in 2017 and headquartered in Plymouth Meeting, PA, the company aims to improve the lives of patients suffering from these conditions.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced an accelerated timeline for its Phase 3 INTUNE study investigating pitolisant for idiopathic hypersomnia (IH). Enrollment is expected to conclude in Q2 2023, with topline data anticipated in Q4 2023. The study aims to assess pitolisant's safety and efficacy against placebo in approximately 200 IH patients across 60 clinical sites in the U.S. An interim analysis confirmed that the trial can proceed with its initial sample size. Harmony's WAKIX, a treatment for narcolepsy, shows promise in addressing the significant unmet needs of IH patients.
Harmony Biosciences Holdings (Nasdaq: HRMY) will participate in several upcoming investor conferences. These events include the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, and the Needham Neuroscience Forum on March 15, 2023, both held virtually, along with the Jefferies Biotech on the Bay Summit in Miami, FL on March 17, 2023. The fireside chats will be available for webcast on Harmony's investor page. This participation highlights Harmony's commitment to advancing therapies for rare neurological diseases.
Harmony Biosciences (NASDAQ: HRMY) has reopened applications for its Patients at the Heart and Progress at the Heart funding programs on February 28, 2023, coinciding with Rare Disease Day. These programs aim to support nonprofit organizations focused on patient-centric initiatives for rare neurological diseases and sleep disorders. Since their launch, these initiatives have funded diverse projects, including educational programs and caregiver retreats, to address the unique challenges faced by patients. Both programs are designed to promote equality and effective messaging within these communities.
Harmony Biosciences Holdings (HRMY) reported a 41% increase in WAKIX net revenue for Q4 2022, totaling $128.3 million, and 43% growth for the full year at $437.9 million. The company achieved a GAAP net income of $181.5 million, with a significant tax benefit contributing to profits. Operating expenses grew, with R&D expenses rising 133.4% to $70.9 million. Ongoing clinical trials, including the Phase 3 IH study, show strong patient enrollment. The company aims to advance programs for Prader-Willi Syndrome and Myotonic Dystrophy, with upcoming clinical data expected in late 2023. Harmony reported cash reserves of $345.7 million as of year-end 2022.